Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

NCT02161575 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab

Sponsor

Novartis Pharmaceuticals